STARMED Received FDA 510(k) Clearance for a Benign Thyroid Nodule Ablation Indication
On 01 July 2026, STARMED America announced that it had received FDA 510(k) clearance for the first radiofrequency ablation (RFA) system in the United States specifically indicated for the treatment of benign thyroid nodules. The clearance made STARMED the first and, at the time, the only company in the U.S. to receive an FDA indication for thyroid nodule RFA, representing a major milestone in the adoption of minimally invasive thyroid treatments.
The FDA-cleared indication covered the company's VIVA combo RF Generator, STARMED RF Electrodes, and VIVA RF Electrodes for ultrasoun...